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Let-7aMicroRNAs negatively regulate target gene expression at the post-transcriptional level during carci-
nogenesis. Recent advances revealed that the expression levels of several miRNAs are up- or down-
regulated in endometrial carcinoma (EC). Here we identify dysregulated miRNAs in EC and we
elucidate the essential role of let-7a. The expression of 86 miRNAs in EC was found to be different
from adjacent normal endometrial tissues. Moreover, miR-let-7 members are down-regulated in
EC and let-7 miRNAs are highly associated with endometrial cancer. A functional investigation
revealed that let-7a suppressed proliferation of HeLa cells by targeting Aurora-B. Let-7a also antag-
onizes Aurora-B functions in promoting carcinoma cell proliferation by down-regulating Aurora-B
protein level. Let-7a could be applied for gene therapy against endometrial carcinogenesis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and lost in mammalian cancers, are highly correlated with humanEndometrial carcinoma (EC) is a high-risk and prevalent cancer
that heavily threatens the health of women all over the world and
the number of estimated new cases of endometrial cancer shows
an increasing trend [1–3]. To date, poor prognostic factors for EC
are used for clinical diagnosis, and no effective therapy for EC
has been established, particularly for the patients with advanced-
stage and recurrent disease [4]. This reﬂects the incomplete under-
standing of the pathogenesis of EC progression on a molecular
level. Identiﬁcation of EC-speciﬁc biomarkers may provide insight
for developing novel therapeutic strategies. Technological ad-
vances in expression proﬁling provide convenient tools for global
screening of dysregulated genes associated with endometrial
carcinogenesis.
MicroRNAs (miRNAs) are a class of short non-coding RNA mol-
ecules (19–25 nucleotides in length) that repress target gene
expression at the post-transcriptional level through incomplete
base-pairing to the 30-untranslated region (30UTR) of target mRNAs
[5,6]. MicroRNAs have been reported to play vital roles in several
developmental processes such as developmental timing, pattern-
ing and neurogenesis [7–9]. Recently, several studies have shown
that aberrant microRNAs (miRNAs) which are frequently gainedcarcinogenesis of lung, breast, ovary and hepatocellular cancers
[5,10–13]. Compelling ﬁndings demonstrate that numerous miR-
NAs acts as tumor suppressors while other miRNAs act as onco-
genes [14,15]. Interestingly, in at least one study, the expression
of most miRNAs was globally down-regulated in tumors compared
with that in normal tissues [11], suggesting that these miRNAs
need to be maintained at relative high expressing level in normal
physiological processes and that miRNAs play important roles in
tumorgenesis.
Previous studies have identiﬁed several dysregulatedmiRNAs in
endometrial carcinogenesis through expression proﬁling. Among
these miRNAs, the miR-200 family is up-regulated in EC tissues
[16] and down-regulated miR-204 mediates EC cell invasion by
targeting FOXC1 [17]. Whereas, distinctive miRNA signatures and
their target mRNAs involved in endometrial carcinogenesis remain
to be fully elucidated. MicroRNA-let-7 was originally found to reg-
ulate cell proliferation and differentiation in Caenorhabditis elegans
[18]. Several let-7 genes are down-regulated to very low expres-
sion level in human cancers, such as breast, colon and lung cancers
[19–22]. Let-7 is a kind of highly conserved miRNAs across species
that is present in multiple genomic locations, and there are ten
mature let-7 isoforms with same seed sequence from 13 precursor
sequences [23]. Let-7 mainly functions as a tumor suppressor to
prevent cancer cell proliferation by targeting tumor genes such
as rat sarcoma (RAS), high-mobility group AT-look 2 (HMGA2)
and c-Myc [24–28]. It is unknown whether miR-let-7 plays an
essential role in endometrial cancer development.
2524 P. Liu et al. / FEBS Letters 587 (2013) 2523–2529In this study, differentially expressed miRNAs in EC were
screened using the Exqion microarray platform and dysregulated
miRNAs were identiﬁed. We veriﬁed the expression of the most
signiﬁcantly dysregulated miRNAs according to the fold change be-
tween endometrial cancer and normal tissues using quantitative
reverse transcriptional-PCR (qRT-PCR). Seven let-7 family mem-
bers were found to be signiﬁcantly down-regulated in EC relative
to adjacent normal endometrial tissues. The biological function of
let-7a was investigated in HeLa cells. Forced expression of let-7a
inhibited HeLa cell proliferation through negative regulation of
Aurora-B expression and antagonized the promotion activity of
Aurora-B on endometrial cancer cell growth. Taken together,
down-regulation of let-7 miRNAs is tightly associated with EC
and let-7a may be suitable for use in gene therapy for endometrial
carcinogenesis.2. Results
2.1. Dysregulated miRNAs in endometrial carcinoma (EC) versus
adjacent normal endometrium (AN)
To study the correlation of miRNAs dysregulation and EC, a
comprehensive expression proﬁle of miRNAs was conducted by
human miRNA arrays in 25 EC and AN tissues. Differentially ex-
pressed miRNAs based on a relative fold-change >1.5 (>500 signal
reads) are listed in Supplementary Table 1. miRNA signatures of EC
versus AN were visibly segregated by unsupervised hierarchical
clustering (Fig. 1A). A total of 203 miRNAs were up-regulated
and 147 were down-regulated in EC compared to that in AN tis-
sues. The heat map suggested that down-regulated miRNAs
showed more signiﬁcant differences between the 2 groups.
To characterize the signiﬁcantly deregulated miRNAs in endo-
metrial cancer samples, miRNAs satisfying the criteria (>ﬁvefold
change between EC versus AN and >500 signal reads) were selected
for clustering (Fig. 1B). Sixteen up-regulated and 70 down-regu-
lated miRNAs were identiﬁed according to this data ﬁltering, which
were considered to be the signiﬁcantly dysregulated miRNA candi-
dates. Notably, more down-regulated miRNAs in EC were present
than up-regulated miRNAs, which is consistent with the ﬁndings
of a previous study showing that global down-regulation of miR-
NAs promotes tumorgenesis [26,29].
To conﬁrm dysregulation of the miRNA candidates, expression
of the highest-ranked 20 miRNAs (10 for up/down regulated miR-
NAs, respectively) was validated using qRT-PCR in 2 sets of speci-
mens (Figure 1C). Most of these candidate miRNAs were
conﬁrmed except miR-548, miR26a/b, and miR-10b. Some up-reg-
ulated miRNAs such as miR-1205, miR-194, and miR-652, have
been demonstrated to be onco-miRNAs in other cancers [30–32].
Furthermore, miRNA-200 up-regulation in EC was conﬁrmed by
our array data [16]. Among candidates showing decreased expres-
sion, miRNA-101, miR-143, miR15a/b, miR-126, and miR-let-7 are
well-documented tumor suppressors, but not in endometrial can-
cer [33–36]. Overall, our data share important similarities with
previous ﬁndings. Collectively, our results of microarray screening
provide valuable information for understanding the pathogenesis
of endometrial carcinogenesis and identiﬁcation of effective thera-
peutic targets.
2.2. Let-7 MicroRNAs were downregulated in EC versus AN
Previously, let-7 has been reported as a tumor suppressor in co-
lon, breast, and lung cancers [19,22,37], whereas the correlation
between let-7 dysregulation and endometrial cancer is less well
known. According to screening data, expression of 7 miR-let-7
members, including let-7a/g/i/d/b/c/e, was signiﬁcantly down-reg-ulated in EC compared to that in AN samples (Fig. 2A, B). Further,
qRT-PCR analysis validated this dysregulation of let-7 miRNA
expression, suggesting that the let-7 microRNA family may play
an essential role in endometrial carcinogenesis. Let-7a was the
most signiﬁcantly changed let-7 miRNA and let-7a/i has been sug-
gested to be down-regulated in EC in global screening [38,39],
although the functions in EC have not been elucidated. Thus, let-
7a was chosen as the candidate miRNA to conduct functional
investigation in EC.
2.3. Aurora-B is a target for let-7a
MicroRNAs exert their functions by inhibiting the expression of
target genes [6]. To investigate the target genes involved in EC,
sequential informatics screening was performed following the
method shown in Figure 3A. Let-7a targets were predicted by four
target prediction websites (Pictar, Targetscan, MirTar and RNAhy-
brid) and overlapped genes were subjected to functional annota-
tion. Tumorgenesis-related genes with reportedly high
expression levels in cancer cells or tissues were narrowed down
to 4 genes: Aurora-B, Myc, HMGA2 and Ras. Except for Aurora-B,
other genes were reported to be let-7 targets [24–28]. The 30UTRs
of these 4 genes were cloned and subjected to a luciferase assay in
293T cells along with let-7a mimics, and we found that let-7a can
signiﬁcantly inhibit the reporter activity of the Aurora-B 30UTR
(Fig. 3B). Additionally, the 30UTR reporter activity of HMGA2 and
Raswas also suppressed by let-7a (Fig. 3B), suggesting that HMGA2
and Ras may be targeted by let-7a in EC.
To further determine the correlation between let-7a and the no-
vel target candidate, let-7a and Aurora-B expression was measured
using qRT-PCR in EC and AN tissues as well as two endometrial
cancer cell lines, HeLa and Ishikawa. The results in Fig. 3C show
that endometrial cancer tissues and cell lines expressed very low
levels of let-7a, which was highly expressed in normal endometrial
tissues. Conversely, Aurora-B showed higher expression levels in
endometrial samples and cell lines compared to that in AN. To fur-
ther conﬁrm the microarray data showing decreased expression of
let-7a in EC, expression of let-7a in additional 30 cancer and nor-
mal specimens was determined by qRT-PCR individually, and sim-
ilar results were obtained (Fig. 3D). Thus, let-7a expression was
inversely correlated with Aurora-B expression. Moreover, align-
ment of let-7a and Aurora-B 30UTR sequences revealed that miR-
let-7a was imperfectly complementary to the only possible let-7a
target site in the Aurora-B 30UTR according to computational pre-
diction (Fig. 3E). To test whether let-7a indeed regulates Aurora-
B, its wild-type 30UTR was mutated by deleting the 7-bp sequence
(D-Mut) complementary to let-7a or by introducing point muta-
tions (Point-Mut) (Fig. 3E). As expected, let-7a down-regulated
the Aurora-B reporter activity, while had no obvious effect on the
mutant reporters (Fig. 3E). Additionally, let-7a overexpression sig-
niﬁcantly reduced the protein level of Aurora-B in HeLa cells.
Meanwhile, let-7g but not let-7f, was capable of decreasing Aur-
ora-B protein expression (Fig. 3F). It is possible that other dysreg-
ulated let-7 miRNA members also regulate Aurora-B expression at
the post-transcriptional level. Collectively, these results indicate
that Aurora-B may be a direct target of miR-let-7a in endometrial
cancer cells.
2.4. Let-7a suppresses the growth of HeLa cells mainly by targeting
Aurora-B
To explore the functional relationship between let-7a and its
target, Aurora-B, in EC, we ﬁrst determined the effect of let-7a on
endometrial cancer cell proliferation. It was found that let-7a over-
expression in HeLa cells, in which endogenous let-7a level is low
(Fig. 3C), signiﬁcantly reduced cell viability and colony formation
Fig. 1. Differential expression proﬁle of microRNAs between endometrial carcinoma (EC) and adjacent normal tissues (AN). (A) Heat map showing the unsupervised ﬁltered
clustering of 350 dysregulated miRNAs in an independent set of EC and AN. (B) Signiﬁcantly dysregulated miRNAs were clustered on the heat map. The ﬁltering criteria were
>ﬁvefold change between EC versus AN and >500 signal reads. log2-transformed scales reﬂect expression levels of indicated miRNAs in (A) and (B). (C) The validation of the
expression of 10 most signiﬁcantly up-regulated and down-regulated miRNAs in EC and AN by qRT-PCR. Expression was normalized to GAPDH.
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effects in endometrial cancer cells. To investigate the role of Aur-
ora-B on cell growth, siRNA targeting to Aurora-B was transfected
into HeLa cells and Aurora-B expression was efﬁciently knocked
down (Fig. 4C). When Aurora-B was co-transfected with let-7a
mimics, Aurora-B protein level was decreased to the control level
(Fig. 4C). We measured cell growth by plotting cell growth curve
and found that HeLa cell growth was suppressed by Aurora-B siR-
NA in a similar manner to let-7a function in HeLa cells, while Aur-
ora-B overexpression signiﬁcantly promoted HeLa cell growth(Fig. 4D). Furthermore, co-transfection of let-7a mimics partially
down-regulated Aurora-B protein levels in Aurora-B-overexpress-
ing cells (Fig. 4C), as well as antagonized the effect of Aurora-B-
elicited growth acceleration (Fig. 4D). Because let-7f has no effect
upon the expression of Aurora-B (Fig. 3F), we also examined the
effects of let-7f overexpression on HeLa cell growth, but no
signiﬁcant difference was observed (Supplementary Fig. 1). These
data further showed that let-7a suppressed cell growth of
endometrial cancer cells mainly by down-regulating Aurora-B
expression.
Fig. 2. let-7 MicroRNAs were downregulated in endometrial carcinoma. (A) Clustered let-7 microRNA in EC versus AN. (B) Raw signals are background-subtracted and
Normalization was performed by using median normalization method. The normalized signal intensity and fold change (ratio and log-2 transformed ratio) of let-7 family
members in AN and EC were shown. (C) qRT-PCR conﬁrmation of down-regulated expression of let-7 microRNA family in EC versus AN.
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Identiﬁcation of differential molecular characteristics between
tumor and normal tissues is helpful for understanding the patho-
genesis of speciﬁc cancers and for developing effective therapeutic
approaches. We have used a comprehensive microarray to screen
microRNAs species that may contribute to endometrial carcinogen-
esis. Previous work has shown that impaired miRNA biogenesis
leads to dysregulation of target oncogenes and oncogenic transfor-
mation [26]. Global reduction of mature miRNA levels has been ob-
served in both human and mouse cancers [11]. Consistently, more
down-regulated miRNAs were identiﬁed in signiﬁcantly dysregu-
lated miRNAs in EC tissues (Fig. 1B), suggesting that down-regula-
tion of miRNAs plays essential roles in EC progression.
Due to the heterogeneity of tumor specimens and the use of dif-
ferent miRNA proﬁling platforms, varying results have been consis-
tently reported [38,40,41]. In this study, we observed
dysregulation of miR-200a/c, miR-193, miR-221, miR-133b, miR-
193a, miR-99b and miR-451a which is consistent with the results
of previous reports [38,39,41,42]. Additionally, qRT-PCR was ap-
plied to validate dysregulated miRNAs in EC. Novel up-regulated
miRNAs (miR-1205, miR-194 and miR-652) and down-regulated
miRNAs (miRNA-101, miR-143, miR15a/b miR-126 and miR-let-
7) were identiﬁed in EC compared to AN samples, most of which
have been proposed as onco-miRNA or tumor suppressors in other
cancers [30–36]. This suggests that these dysregulated miRNAs are
also associated with endometrial carcinogenesis.
Importantly, we found that expression of most let-7 miRNA
family members was decreased in EC relative to AN (Fig. 2). Let-7
has been proposed as a tumor suppressor in human lung and colon
cancers [19–22], whereas it remains unclear whether let-7 plays
important roles in EC, although let-7a/i has been suggested to be
dysregulated in gene proﬁling experiments [38,39]. Our validation
of expression of let-7 family members suggested that the distinct
expression levels of let-7a/g/i/d/b/c/e could be used to distinguish
EC from normal endometrial tissues, which may be of signiﬁcant
diagnostic value for EC when combined with other clinical
approaches.
Of the most signiﬁcantly dysregulated miRNAs, let-7a was high-
lighted for further functional analysis to identify its role in endo-metrial cancer. Through target prediction and functional
ﬁltration, Aurora-B was considered to be a novel let-7a target can-
didate in EC. Aurora-B is an evolutionary conserved serine/threo-
nine kinase that plays important roles in chromosome movement
such as condensation and segregation [43]. Aurora-B is mainly ex-
pressed during the proliferative phase in normal endometrium
cells and its expression is correlated with endometrial carcinoma
[44,45]. In our study, let-7a expression is inversely related to Aur-
ora-B mRNA levels in AN versus EC and endometrial cell lines
(Fig. 3C). Luciferase assays and western blotting analysis showed
that let-7a inhibited Aurora-B by directly targeting its 30-UTR
(Fig. 3).
MicroRNAs promote tumorgenesis by inﬂuencing cell prolifera-
tion and apoptotic processes. To further explore the functional
relationship between let-7a and Aurora-B in EC, their correlated
roles in cell growth of EC cells were elucidated. We found that
let-7a prevented cell proliferation, whereas Aurora-B promoted
the cell growth of HeLa cells. Importantly, let-7a antagonizes Aur-
ora-B-induced promotion of cell proliferation by down-regulating
Aurora-B expression levels. However, apoptosis of HeLa cells was
not affected by let-7a mimics (data not shown), suggesting that
let-7a might exert its functions by targeting Aurora-B and further
inﬂuencing the cell division. Further investigation is required to
elucidate the speciﬁc mechanism by which let-7a affects cell cycle
events.
In conclusion, we identiﬁed a novel set of dysregulated miRNAs,
including miR-1205, miR-194, miR-652, miRNA-101, miR-143,
miR15a/b, and miR-126, that can be used to differentiate EC from
normal endometrium. Moreover, down-regulation of let-7 microR-
NA family member expression is closely related to endometrial
cancer and let-7a mediates the growth of endometrial cancer cells
by regulating Aurora-B expression. Our study elucidated the
crucial roles of deregulated miRNAs in endometrial carcinogenesis
and it is valuable to explore the pathological cause of miRNAs
desregulation in EC progression in the future study. The identiﬁed
miRNAs and Aurora-B corporately provide novel diagnostic
biomarkers for endometrial cancer, and targeting of
dysregulated miRNAs (such as let-7) and Aurora-B may aid in the
development of novel therapeutic approaches for endometrial
carcinoma.
Fig. 3. Aurora-B is a target of let-7a in endometrial cancer cell lines. (A) The ﬂow of let-7a targets prediction and ﬁltering. (B) Let-7a mimics or control RNA (Ctrl) was co-
transfected with 3’UTR of 4 genes (Aurora-B, Myc, HMGA2 and Ras) and pRL-TK into 293T cells. Luciferase activity was determined 24 h post-transfection. (C) The relative
expression level of let-7a and Aurora-B was examined by qRT-PCR in pooled samples of AN and EC tissues and Ishikawa & HeLa cell lines. The expression of let-7a was
normalized to U6 RNA and the relative expression of let-7a was set at 1 in AN. The expression of Aurora-B was normalized to GAPDH and the relative expression of Aurora-B
was set at 1 in EC. (D) Expression of let-7a was veriﬁed in 30 recently collected cancer and adjacent normal tissues using qRT-PCR. (E) The seed sequence of let-7a is shown in
upper case. The sequences of wild-type (Aurora-B 30UTR) and deletion mutant (D-Mut) or point mutatant (Point-Mut) in 30UTR luciferase reporters are shown in lower case.
Aurora-B 3’UTR and mutated 30UTR luciferase report assays were performed in 293T cells. (F) Control RNA (Ctrl), let-7a, let-7 g or let-7f mimics were transfected into HeLa
cells, respectively and the protein levels of Aurora-B and GAPDH were determined 48 h post-transfection by western blotting.
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4.1. Ethics statement
The study protocol was approved by the ethics review board of
Infant Health Hospital, Shanghai, China. Written informed consent
was obtained from all study participants. All of the procedures
were conducted in accordance with the Declaration of Helsinki
and relevant policies in China.
4.2. Samples and cell lines
A total of 25 surgically resected patients with stage-2 EC (19 pa-
tients were in grade 1 and 6 patients were in grade 2) were en-
rolled. Patients were histologically examined by the pathology
department of Changning Maternity and Infant Health Hospital.
Specimens from cancer tissues and adjacent normal tissues were
collected. All samples were individually fresh-frozen in TRIzol Re-
agent (Invitrogen, Carlsbad, CA). Cancer and normal samples were
pooled together respectively until 25 specimens were collected.
Each group of samples was divided for microarray analysis and
for qRT-PCR validation. Clinical staging was performed following
the International Federation of Gynecology and Obstetrics stan-
dards. To conﬁrm the expression patterns in endometrial cancer,
another 30 cancer and adjacent normal tissue samples were col-lected separately for let-7a expression analysis. Informed consent
was obtained from each patient prior to surgery. HeLa and Ishika-
wa cells were originally obtained from ATCC and cultured accord-
ing to ATCC guidelines.
4.3. Microarray and analysis
Fresh-frozen EC and normal endometrium samples in TRIzol re-
agent were delivered to KangChen Bio-tech (Shanghai, China).
MicroRNA isolation, quantity testing, miRNA labeling and analysis
were performed by this corporation. Normalization was performed
by KangChen Bio-tech using median normalization method. La-
beled RNA was hybridized to the Exiqon human miRNA microarray
(V11.0), and over 1000 human miRNAs were probed for expression
analysis. Heat mapping was performed using Cluster 3.0 and JAVA
Treeview softwares.
4.4. RNA isolation and quantitative real-time PCR
Total RNA was isolated from tissue samples with TRIzol Reagent
(Invitrogen) according to the manufacturer’s instructions. For
miRNA quantiﬁcation, 20 ng of total RNAs was used with the
TaqMan MicroRNA Assay Kit (Applied Biosystems, Foster City,
CA). For mRNA analysis, 5 lg total RNA was reverse transcribed
using SuperScript III Reverse Transcriptase (Invitrogen) and
Fig. 4. let-7a suppresses the growth of HeLa cells by targeting Aurora-B. (A) The effects of let-7a overexpression on cell viability were detected by MTT assay. (B) The effects of
let-7a on the cell proliferation capacity of HeLa cells were determined using the colony formation assay. (C) HeLa cells in 24-well plates were transfected as indicated (siR-
Ctrl + Vec: control siRNA and overexpression vectors; siR-Aurora-B + Vec: Aurora-B siRNA and overexpression vectors; Aurora-B OV + Ctrl RNA: Aurora-B overexpression and
control RNA; Aurora-B OV + let-7a: Aurora-B overexpression and let-7a mimics). Note that the amount of tranfected Aurora-B overexpressing plasmid or vector plasmid was
100 ng per well and the concentration of let-7a mimics was 50 nm. The protein level of Aurora-B was determined by western blotting. (D) Cell growth of HeLa cells was
determined by plotting cell growth curve when HeLa cells were transfected with indicated combinations of transfections under the same conditions in (C). The effect of let-7a
alone on cell growth was also determined (Ctrl RNA: control RNA; let-7a: let-7a mimics).
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4.5. Luciferase reporter assay
The 30-UTRs of Aurora-B (NM_004217, 1100–1295), Myc
(NM_002467, 1890–2250), HMGA2 (NM_003483, 1142–1627)
and Ras (NM_005343, 758–1040) were ampliﬁed from human
genomic DNA and constructed into a modiﬁed pGL3 vector from
pGL3-control plasmid (Promega, Fitchburg, WI), which was in-
serted with a multiple cloning site (MCS) following the luciferase
element. The 30-UTRs were cloned into the reporter plasmid using
EcoR1 and Pst1 at the inserted MCS. Each reporter construct was
co-transfected with pRL-TK and RNA oligonucleotides (let-7a mim-
ics or control RNA (Ambion, Austin, TX)) or vectors into 293T cells.
Sequences of synthetic let-7a were: sense (50-UGAGGUA-
GUAGGUUGUAUAGUU-30); anti-sense (50-CUAUACAACCUACUAC-
CUCAUU-30). Cells were harvested for the dual luciferase reporter
assay (Promega) after transfection for 48 h.
4.6. Western blotting analysis
Cells were harvested in lysates lysis buffer containing 150 mM
NaCl, 50 mM Tris–HCl (pH 8.0), 0.1% SDS, 0.5% sodium deoxycho-
late, 5 mM EDTA, 1% Nonidet P-40, 0.25 mM phenylmethanesulfo-
nyl ﬂuoride, and protease inhibitors. Lysates were subjected to a
polyvinylidene ﬂuoride membrane, followed by blocking in with
5% skimmilk and immunoblotting with anti-Aurora-B (1:1000, Ab-
cam, Cambridge, MA) and anti-GAPDH (1:10000, Abcam).
4.7. RNA Interference and Transient Transfection
Silencing of Aurora-B was achieved by transfection of siRNAs
targeting human Aurora-B mRNA. Scrambled control and Aurora-
B siRNA duplexes were chemically synthesized by Shanghai Gene-
Chem Co. Ltd, and had the following sequences: Control (50-GAAAGUCCUGCCAUCGCACUCtt-30); Aurora-B (50-AAGAGCCUGU-
CACCCCAUCUGtt-30) [46].
Transfections were performed using a Lipofectamine 2000 re-
agent (Invitrogen) following the manufacturer’s instructions. The
concentration of transfected miRNA mimics or control RNA was
50 nM.
4.8. Cell proliferation assay
Cell viability was detected using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay and soft agar
colony formation assay as described previously [47,48]. A cell
growth curve was constructed by cell number counting after 24 h
post-transfection in 24-well plates. The mean values of 3 wells
were calculated as the the cell number for every 2 days.
4.9. Statistical analysis
Statistical analyses were performed using the GraphPad Prism 5
software, and data are presented as the mean ± SD. Functional
experiments in HeLa cells were obtained from three independent
experiments. For evaluation of gene expression within different
samples, Student’s t-tests were performed to compare the signiﬁ-
cance of differences between groups. Differences were considered
statistically signiﬁcant at ⁄f diagnostic p < 0.05.
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